MENU

ALMS Alumis Inc. Forecast, Technical & Fundamental Analysis

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases... Show more

ALMS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
View a ticker or compare two or three
ALMS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
280 East Grand Avenue
Phone
+1 650 231-6625
Employees
224
Web
https://www.alumis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SHG80.951.36
+1.71%
Shinhan Financial Group Co Ltd
TNXP9.860.16
+1.65%
Tonix Pharmaceuticals Holding Corp
CATY61.450.32
+0.52%
Cathay General Bancorp
PUBM18.600.05
+0.27%
PubMatic
IQST0.99-0.01
-1.19%
iQSTEL Inc.

ALMS and Stocks

Correlation & Price change

A.I.dvisor tells us that ALMS and MRNA have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALMS and MRNA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALMS
1D Price
Change %
ALMS100%
-2.61%
MRNA - ALMS
30%
Poorly correlated
+2.08%
DRUG - ALMS
29%
Poorly correlated
-3.20%
ZNTL - ALMS
28%
Poorly correlated
-1.82%
VKTX - ALMS
27%
Poorly correlated
-3.24%
SNDX - ALMS
27%
Poorly correlated
+1.28%
More
Alumis (ALMS) stock Forecast, Price Targets and Analysts Predictions - Tickeron.com